Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068730 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01068730 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 28 participants.
The verdict
NCT01068730, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
To demonstrate the bioequivalence of 500 mg and 1000 mg Glucophage tablets manufactured by BMS relative to the respective strengths of 500 mg and 1000 mg Diabex tablets marketed in Australia by Alphapharm in the fed state
Interventions
- DRUG metformin (Diabex)
- DRUG metformin (Glucophage™)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068730
The ClinicalTrials.gov registry entry for NCT01068730 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which metformin (Diabex) is the first listed.
NCT01068730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01068730 about?
NCT01068730 is a clinical study titled "Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects". To demonstrate the bioequivalence of 500 mg and 1000 mg Glucophage tablets manufactured by BMS relative to the respective strengths of 500 mg and 1000 mg Diabex tablets marketed in Australia by Alphapharm in the fed state
What is the current status of trial NCT01068730?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-02. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01068730?
The interventions under investigation include: metformin (Diabex) (DRUG), metformin (Glucophage™) (DRUG).
Who is sponsoring clinical trial NCT01068730?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.